NewAmsterdam Pharma Company N.V. — Cyborg Score 7/10
Strong
Biopharmaceutical / Clinical-Stage Drug Development
Strategic Profile
Trading at approximately 35x earnings multiples with significant upside potential, NewAmsterdam has built a focused pipeline around obicetrapib's mechanism. The company demonstrates strong analyst confidence (12 of 12 buy ratings) and trades substantially below peer valuation estimates, positioning it as a differentiated player in the competitive metabolic disease space.
Cyborg Score Rationale
Late-stage clinical company with a validated lead asset showing strong regulatory and clinical progress. Consensus analyst support and substantial market cap ($3.94B) indicate institutional confidence, though pre-revenue status introduces execution risk. Multiple clinical indications (cardiovascular, Alzheimer's) provide diversification.
Top Insights
Lead asset obicetrapib in late-stage development as monotherapy and combination therapy for LDL-C reduction in cardiovascular disease
Secondary indication in Phase 2a for Alzheimer's disease expands market opportunity beyond cardiology
Consensus buy rating from 12 analysts with average 12-month price target of $49.08 (38% upside from current levels)
Trading 80.8% below fair value estimates per independent analysis, suggesting significant valuation discount relative to comparable biotech peers
Named Competitors
CETP Inhibitors — Traditional CETP inhibitor programs with different safety/efficacy profiles
PCSK9 Inhibitors — Established LDL-lowering class with significant market penetration